FDA’s Post-market Safety Reviews Of NMEs Find Timing May Not Be Everything
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial results from pilot show drugs marketed for longer offer more telling data for safety recommendations, but the number of treated patients also may be a factor.